{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:20:52Z","timestamp":1744258852223,"version":"3.40.4"},"reference-count":67,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"3","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Introduction: Atopic dermatitis is a chronic, systemic, relapsing disease with dermatological manifestations, which imposes a high burden on patients, families and the health care system and has a high psychological,\u00a0social, and economic impact and on the quality of life of patients. It mainly affects the pediatric population and,\u00a0to a lesser extent, the adult population. The clinical presentation varies according to the age and evolution of\u00a0the disease, and currently there are multiple pharmacological and non-pharmacological therapies available for\u00a0the symptomatic management of patients.\nObjective: To present an algorithm for the management of atopic dermatitis, proposed as a series of recommendations\u00a0on the management, diagnosis, education, and follow-up of these patients.\nMethods: A consensus was reached using the nominal group technique. The methodology was developed in\u00a07 phases, including: posing the research questions, literature search, an initial proposal of recommendations,\u00a0elaboration of the final recommendations and the management algorithm with three voting cycles, consensus\u00a0was established with 80% favorability.\nResults and conclusions: The result of the consensus process is a management algorithm for patients with\u00a0mild, moderate\/severe atopic dermatitis derived from expert recommendations. The algorithm establishes diagnostic\u00a0and treatment criteria and provides updated recommendations, including all therapeutic alternatives\u00a0available in Peru for the management of patients with mild, moderate, and severe atopic dermatitis.<\/jats:p>","DOI":"10.29262\/ram.v70i3.1228","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T08:04:30Z","timestamp":1694505870000},"page":"167-186","source":"Crossref","is-referenced-by-count":0,"title":["Algoritmo de tratamiento de la dermatitis at\u00f3pica en Per\u00fa. Consenso de expertos","Algorithm for the management of atopic dermatitis in Peru - Expert consensus"],"prefix":"10.29262","volume":"70","author":[{"given":"Pablo","family":"Butron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Galvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosal\u00eda","family":"Ballona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyin Giuliana","family":"Castro Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Bravo Puccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Enrique","family":"Gerada Solari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Ignacio","family":"Larco Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Matos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Torres Iberico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"57519","doi-asserted-by":"crossref","unstructured":"Giachetti A, Castro C, Greco MF, Scacchi MF, et al. Consenso Nacional de Dermatitis At\u00f3pica 2013. Resumen ejecutivo. Arch Argent Pediatr. 2014; 12 (3): 293-4. DOI: 10.5546\/aap.2014.293","DOI":"10.5546\/aap.2014.293"},{"key":"57520","doi-asserted-by":"crossref","unstructured":"Sastre J, Baldrich ES, Armario Hita JC, Herra\u00e9z L, et al. Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey. Dermatol Res Pract. 2020; 2020. DOI: 10.1155\/2020\/1524293","DOI":"10.1155\/2020\/1524293"},{"key":"57521","doi-asserted-by":"crossref","unstructured":"Slattery MJ, Essex MJ, Paletz EM, Vanness ER, et al. Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011; 128 (3): 668. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3164894\/","DOI":"10.1016\/j.jaci.2011.05.003"},{"key":"57522","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatology Venereol. 2018; 32 (5): 657-82. DOI: 10.1111\/jdv.14891","DOI":"10.1111\/jdv.14891"},{"key":"57523","doi-asserted-by":"crossref","unstructured":"Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol . 2018; 36 (5): 595-605. https:\/\/pubmed.ncbi.nlm.nih.gov\/30217272\/","DOI":"10.1016\/j.clindermatol.2018.05.007"},{"key":"57524","doi-asserted-by":"crossref","unstructured":"Son JH, Chung BY, Kim HO, Park CW. Clinical features of atopic dermatitis in adults are different according to onset. J Korean Med Sci. 2017; 32 (8): 1360-6. https:\/\/pubmed.ncbi.nlm.nih.gov\/28665074\/","DOI":"10.3346\/jkms.2017.32.8.1360"},{"key":"57525","doi-asserted-by":"crossref","unstructured":"Magnifico I, Petronio GP, Venditti N, Cutuli MA, et al. Atopic Dermatitis as a Multifactorial Skin Disorder. Can the Analysis of Pathophysiological Targets Represent the Winning Therapeutic Strategy? Pharmaceuticals. 2020; 13 (11): 1-18. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7700401\/","DOI":"10.3390\/ph13110411"},{"key":"57526","doi-asserted-by":"crossref","unstructured":"Nacional C, Dra DD, Giachetti A, Mar\u00eda D, et al. Consenso Nacional de Dermatitis At\u00f3pica 2013. Arch Argent Pediatr. 2014; 1-21. DOI: 10.5546\/aap.2014.293","DOI":"10.5546\/aap.2014.293"},{"key":"57527","doi-asserted-by":"crossref","unstructured":"Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980; (92 (Suppl 1): 44-7.","DOI":"10.2340\/00015555924447"},{"key":"57528","doi-asserted-by":"crossref","unstructured":"Wu\u0308thrich B, Schmid-Grendelmeier P. The atopic eczema\/dermatitis syndrome: Epidemiology, natural course, and immunology of the IgE-associated (\u201cextrinsic\u201d) and the nonallergic (\u201cintrinsic\u201d) AEDS. J Invest Allergol Clin Immunol. 2003; 13 (1): 1-5. https:\/\/pubmed.ncbi.nlm.nih.gov\/12861844\/","DOI":"10.3109\/9780203908877-2"},{"key":"57529","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Oranje A, Deleuran M, Simon D, et al. ETFAD\/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatology Venereol. 2016; 30 (5): 729-47. https:\/\/pubmed.ncbi.nlm.nih.gov\/27004560\/","DOI":"10.1111\/jdv.13599"},{"key":"57530","doi-asserted-by":"crossref","unstructured":"Vestergaard C, Wollenberg A, Barbarot S, Christen-Zaech S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatology Venereol. 2019; 33 (9): 1644-59. DOI: 10.1111\/jdv.15709","DOI":"10.1111\/jdv.15709"},{"key":"57531","doi-asserted-by":"crossref","unstructured":"Damiani G, Calzavara-Pinton P, Stingeni L, Hansel K, et al. Italian guidelines for therapy of atopic dermatitis\u2014Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). Dermatol Ther. 2019; 32 (6): 1-10. DOI: 10.1111\/dth.13121","DOI":"10.1111\/dth.13121"},{"key":"57532","doi-asserted-by":"crossref","unstructured":"McMillan SS, King M TM. How to use the nominal group and Delphi techniques. Int J Clin Pharm. 2016; 38 (3): 655-62. DOI: 10.1007\/s11096-016-0257-x","DOI":"10.1007\/s11096-016-0257-x"},{"key":"57533","unstructured":"Potter M, Gordon S, Hamer WP. The Nominal Group Technique: A Useful Consensus Methodology in Physiotherapy Research. New Zeal J Physiother. 2008; 32: 126-30. https:\/\/www.researchgate.net\/publication\/254724490_The_Nominal_Group_Technique_"},{"key":"57534","unstructured":"A_useful_consensus_methodology_in_physiotherapy_research"},{"key":"57535","doi-asserted-by":"crossref","unstructured":"Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995; 311 (7001): 376-80. DOI: 10.1136\/bmj.311.7001.376.","DOI":"10.1136\/bmj.311.7001.376"},{"key":"57536","doi-asserted-by":"crossref","unstructured":"Eichenfield LF. Consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy Eur J Allergy Clin Immunol Suppl. 2004; 59 (78): 86-92. https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/j.1398-9995.2004.00569.x","DOI":"10.1111\/j.1398-9995.2004.00569.x"},{"key":"57537","doi-asserted-by":"crossref","unstructured":"Kulthanan K, Tuchinda P, Nitiyarom R, Chunharas A, et al. Clinical practice guidelines for the diagnosis and management of atopic dermatitis. Asian Pacific J Allergy Immunol. 2021; 39 (3): 145-55. DOI: 10.12932\/AP-010221-1050","DOI":"10.12932\/AP-010221-1050"},{"key":"57538","doi-asserted-by":"crossref","unstructured":"Russo F, Milanesi N, Iannone M, Bagnoni G, et al. Tuscan Consensus on the diagnosis, treatment and follow-up of adult atopic dermatitis. G Ital di Dermatologia e Venereol. 2020; 155 (3): 253-60. DOI: 10.23736\/S0392-0488.19.06527-1","DOI":"10.23736\/S0392-0488.19.06527-1"},{"key":"57539","unstructured":"Costanzo A, Amerio P, Asero R, Chiricozzi A, et al. Long-term management of moderate-to-severe adult atopic dermatitis: A consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian"},{"key":"57540","doi-asserted-by":"crossref","unstructured":"Associ. Ital J Dermatology Venereol. 2022; 157 (1): 1-12. DOI: 10.23736\/S2784-8671.21.07129-2","DOI":"10.23736\/S2784-8671.21.07129-2"},{"key":"57541","unstructured":"Rinc\u00f3n-P\u00e9rez C, Larenas-Linnemann D, Figueroa-Morales MA, Luna-Pech J, et al. Mexican consensus on the diagnosis and treatment of atopic dermatitis in adolescents and adults. Rev"},{"key":"57542","doi-asserted-by":"crossref","unstructured":"Alerg Mex. 2018; 65: S8-88. DOI: 10.29262\/ram.v65i6.526","DOI":"10.29262\/ram.v65i6.526"},{"key":"57543","doi-asserted-by":"crossref","unstructured":"2Hong CH, Gooderham MJ, Albrecht L, Bissonnette R, et al. Approach to the assessment and management of adult patients with atopic dermatitis: A consensus document. Section v: Consensus statements on the assessment and management of adult patients with moderate-to-severe atopic dermatitis. J Cutan Med Surg. 2018; 22: 30S-35S. DOI: 10.1177\/1203475418803625","DOI":"10.1177\/1203475418803625"},{"key":"57544","doi-asserted-by":"crossref","unstructured":"Patruno C, Amerio P, Chiricozzi A, Costanzo A, et al. Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: Joint recommendations of the Italian Society of Dermatology and Venereology (SIDeMaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergologic. G Ital di Dermatologia e Venereol. 2020; 155 (1): 1-7. DOI: 10.23736\/S0392-0488.19.06522-2","DOI":"10.23736\/S0392-0488.19.06522-2"},{"key":"57545","doi-asserted-by":"crossref","unstructured":"Kannenberg SM, Karabus S, Visser WI, Aboobaker J, et al. Paediatric atopic eczema (Atopic dermatitis) in south africa: A practical algorithm for the management of mild-to-moderate disease in daily clinical practice. South African Fam Pract. 2020; 62 (1): 1-9. DOI: 10.4102\/safp.v62i1.5190","DOI":"10.4102\/safp.v62i1.5190"},{"key":"57546","doi-asserted-by":"crossref","unstructured":"Agache I, Song Y, Posso M, Alonso-Coello P, et al. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. Allergy Eur J Allergy Clin Immunol. 2021; 76 (1): 45-58. DOI: 10.1111\/all.14510","DOI":"10.1111\/all.14510"},{"key":"57547","doi-asserted-by":"crossref","unstructured":"Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection. J Allergy Clin Immunol Pract. 2020; 8 (1): 91-101. DOI: 10.1016\/j.jaip.2019.06.044","DOI":"10.1016\/j.jaip.2019.06.044"},{"key":"57548","doi-asserted-by":"crossref","unstructured":"Rullo VEV, Segato A, Kirsh A, Sole D. Severity scoring of atopic dermatitis: a comparison of two scoring systems. Allergol Immunopathol (Madr). 2008; 36 (4): 205-11. http:\/\/dx.doi.org\/10.1016\/S0301-0546(08)72551-5","DOI":"10.1157\/13127044"},{"key":"57549","doi-asserted-by":"crossref","unstructured":"Kim JE, Shin MK, Park GH, Lee UH, et al. 2019 consensus Korean diagnostic guidelines to define severity classification and treatment refractoriness for atopic dermatitis: Objective and subjective assessment of severity. Ann Dermatol. 2019; 31 (6): 654-61. DOI: 10.5021\/ad.2019.31.6.654","DOI":"10.5021\/ad.2019.31.6.654"},{"key":"57550","doi-asserted-by":"crossref","unstructured":"Perez-Chada L, Taliercio VL, Gottlieb A, Van Beek M, et al. Achieving Consensus on Patient-Reported Outcome Measures in Clinical Practice for Inflammatory Skin Disorders. J Am Acad Dermatol. 2019. https:\/\/doi.org\/10.1016\/j.jaad.2019.09.008","DOI":"10.1016\/j.jaad.2019.09.008"},{"key":"57551","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, et al. Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatology. 2020; 156 (8): 863-73. DOI: 10.1001\/jamadermatol.2020.1406","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"57552","doi-asserted-by":"crossref","unstructured":"Chopra R, Silverberg JI. Assessing the severity of atopic dermatitis in clinical trials and practice. Clin Dermatol. 2018; 36 (5): 606-15. https:\/\/doi.org\/10.1016\/j.clindermatol.2018.05.012","DOI":"10.1016\/j.clindermatol.2018.05.012"},{"key":"57553","doi-asserted-by":"crossref","unstructured":"Yang YB, Lynde CW, Fleming P. Common Atopic Dermatitis Rating Scales: A Practical Approach and Brief Review. J Cutan Med Surg. 2020; 24 (4): 399-404. DOI: 10.1177\/1203475420923644","DOI":"10.1177\/1203475420923644"},{"key":"57554","doi-asserted-by":"crossref","unstructured":"Calzavara-Pinton P, Fortina AB, Bonamonte D, Marseglia GL, et al. Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDemaSt), the Italian association of Hospital Dermatologists and Public Health (aDoI), the Italian associa. Ital J Dermatology Venereol. 2021; 156 (2): 184-97. DOI: 10.23736\/S2784-8671.20.06654-7","DOI":"10.23736\/S2784-8671.20.06654-7"},{"key":"57555","doi-asserted-by":"crossref","unstructured":"Smith S, Baker C, Gebauer K, Rubel D, et al. Atopic dermatitis in adults: An Australian management consensus. Australas J Dermatol. 2020; 61 (1): 23-32. DOI: 10.1111\/ajd.13124","DOI":"10.1111\/ajd.13124"},{"key":"57556","doi-asserted-by":"crossref","unstructured":"Barbarot S, Boralevi F, Shourick J, Sampogna F, et al. Characteristics of children and adolescents with atopic dermatitis who attended therapeutic patient education. J Eur Acad Dermatology Venereol. 2021; 35 (11): 2263-9. DOI: 10.1111\/jdv.17526","DOI":"10.1111\/jdv.17526"},{"key":"57557","doi-asserted-by":"crossref","unstructured":"Dhadwal G, Albrecht L, Gniadecki R, Poulin Y, et al. Approach to the assessment and management of adult patients with atopic dermatitis: A consensus document. Section IV: Treatment options for the management of atopic dermatitis. J Cutan Med Surg. 2018; 22: 21S-29S. DOI: 10.1177\/1203475418805721","DOI":"10.1177\/1203475418805721"},{"key":"57558","doi-asserted-by":"crossref","unstructured":"Reda AM, Elgendi A, Ebraheem AI, Aldraibi MS, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas. J Dermatolog Treat. 2019; 30 (4): 366-73. https:\/\/doi.org\/10.1080\/09546634.2018.1524823","DOI":"10.1080\/09546634.2018.1524823"},{"key":"57559","doi-asserted-by":"crossref","unstructured":"Patrizi A, Costanzo A, Patruno C, Bus\u00e0 VM, et al. Unmet needs in atopic dermatitis management: an expert consensus. J Dermatolog Treat. 2022; 33 (5): 2459-65. https:\/\/doi.org\/10.1080\/09546634.2021.1967267","DOI":"10.1080\/09546634.2021.1967267"},{"key":"57560","doi-asserted-by":"crossref","unstructured":"Iannone M, Tonini G, Janowska A, Dini V, et al. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review. Curr Med Res Opin. 2021; 37 (8): 1295-301. https:\/\/doi.org\/10.1080\/03007995.2021.1933929","DOI":"10.1080\/03007995.2021.1933929"},{"key":"57561","doi-asserted-by":"crossref","unstructured":"Thomas KS, Apfelbacher CA, Chalmers JR, Simpson E, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*. Br J Dermatol. 2021; 185 (1): 139-46. DOI: 10.1111\/bjd.19751","DOI":"10.1111\/bjd.19751"},{"key":"57562","doi-asserted-by":"crossref","unstructured":"Boguniewicz M, Alexis AF, Beck LA, Block J, et al. Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. J Allergy Clin Immunol Pract. 2017; 5 (6): 1519-31. https:\/\/doi.org\/10.1016\/j.jaip.2017.08.005","DOI":"10.1016\/j.jaip.2017.08.005"},{"key":"57563","doi-asserted-by":"crossref","unstructured":"Lynde CW, Bourcier M, Gooderham M, Guenther L, et al. A treatment algorithm for moderate to severe atopic dermatitis in adults. J Cutan Med Surg. 2018; 22 (1): 78-83. DOI: 10.1177\/1203475417733460","DOI":"10.1177\/1203475417733460"},{"key":"57564","doi-asserted-by":"crossref","unstructured":"Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, et al. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. J Allergy Clin Immunol Pract. 2021; 9 (3): 1053-65. DOI: 10.1016\/j.jaip.2020.11.034","DOI":"10.1016\/j.jaip.2020.11.034"},{"key":"57565","doi-asserted-by":"crossref","unstructured":"Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019; 28 (7): 756-68. DOI: 10.1111\/exd.13911","DOI":"10.1111\/exd.13911"},{"key":"57566","doi-asserted-by":"crossref","unstructured":"Li H, Zhang Z, Zhang H, Guo Y, et al. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol. 2021; 61 (3): 324-38. https:\/\/doi.org\/10.1007\/s12016-021-08880-3","DOI":"10.1007\/s12016-021-08880-3"},{"key":"57567","doi-asserted-by":"crossref","unstructured":"Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018; 178 (3): 768-75. DOI: 10.1111\/bjd.15928","DOI":"10.1111\/bjd.15928"},{"key":"57568","doi-asserted-by":"crossref","unstructured":"Boguniewicz M. Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines. J Allergy Clin Immunol Pract. 2017; 5 (6): 1477-87. https:\/\/doi.org\/10.1016\/j.jaip.2017.08.031","DOI":"10.1016\/j.jaip.2017.08.031"},{"key":"57569","doi-asserted-by":"crossref","unstructured":"Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, et al. Systemic treatments for eczema: a network meta-analysis. Cochrane Database Syst Rev. 2020; 2020 (9). DOI: 10.1002\/14651858.CD013206.pub2","DOI":"10.1002\/14651858.CD013206.pub2"},{"key":"57570","doi-asserted-by":"crossref","unstructured":"Ghazal S, Ridha Z, Nassim D, D\u2019aguanno K, et al. 456 Mapping recommendations of recent guidelines for adult atopic dermatitis. J Invest Dermatol. 2021; 141 (5): S79. DOI: 10.1016\/j.jid.2021.02.479","DOI":"10.1016\/j.jid.2021.02.479"},{"key":"57571","doi-asserted-by":"crossref","unstructured":"Calzavara Pinton P, Cristaudo A, Foti C, Canonica GW, et al. Diagnosis and management of moderate to severe adult atopic dermatitis: A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Cli. G Ital di Dermatologia e Venereol. 2018; 153 (2): 133-45. DOI: 10.23736\/S0392-0488.17.05892-8","DOI":"10.23736\/S0392-0488.17.05892-8"},{"key":"57572","doi-asserted-by":"crossref","unstructured":"Zhou S, Qi F, Gong Y, Zhang J, et al. Biological Therapies for Atopic Dermatitis: A Systematic Review. Dermatology. 2021; 237 (4): 542-52. DOI: 10.1159\/000514535","DOI":"10.1159\/000514535"},{"key":"57573","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Toth D, Bieber T, Alexis AF, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III EC ZTRA 3 trial*. Br J Dermatol. 2021; 184 (3): 450-63. DOI: 10.1111\/bjd.19573","DOI":"10.1111\/bjd.19573"},{"key":"57574","doi-asserted-by":"crossref","unstructured":"De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, et al. Treat-to-target in atopic dermatitis: An international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021; 101 (2): 1-7. DOI: 10.2340\/00015555-3751","DOI":"10.2340\/00015555-3751"},{"key":"57575","doi-asserted-by":"crossref","unstructured":"Lopes C, Neto M, Rageteiro F, Marcelino J, et al. Protocolo cl\u00ednico de avalia\u00e7\u00e3o de doentes adultos com dermatite at\u00f3pica em tratamento com Dupilumab. Rev Port Imunoalergologia. 2019; 27 (2): 135-45.","DOI":"10.32932\/rpia.2019.07.011"},{"key":"57576","doi-asserted-by":"crossref","unstructured":"Silverberg JI, de Bruin-Weller M, Bieber T, Soong W, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. J Allergy Clin Immunol. 2022; 149 (3): 977-987.e14. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.036","DOI":"10.1016\/j.jaci.2021.07.036"},{"key":"57577","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatology Venereol. 2021; 35 (9): 1797-810. DOI: 10.1111\/jdv.17351","DOI":"10.1111\/jdv.17351"},{"key":"57578","doi-asserted-by":"crossref","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020; 396 (10246): 255-66. http:\/\/dx.doi.org\/10.1016\/S0140-6736(20)30732-7","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"57579","doi-asserted-by":"crossref","unstructured":"Custo Greig E, Brigell M, Cao F, Levine ES, et al. Macular and Peripapillary Optical Coherence Tomography Angiography Metrics Predict Progression in Diabetic Retinopathy: A Sub-analysis of TIME-2b Study Data. Am J Ophthalmol. 2020; 219: 66-76. https:\/\/pubmed.ncbi.nlm.nih.gov\/32574773\/","DOI":"10.1016\/j.ajo.2020.06.009"},{"key":"57580","doi-asserted-by":"crossref","unstructured":"Agache I, Akdis CA, Akdis M, Brockow K, et al. EAACI Biologicals Guidelines\u2014dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy Eur J Allergy Clin Immunol. 2021; 76 (4): 988-1009. DOI: 10.1111\/all.14690","DOI":"10.1111\/all.14690"},{"key":"57581","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, et al. Treatment of atopic dermatitis with tralokinumab, an anti\u2013IL-13 mAb. J Allergy Clin Immunol. 2019; 143 (1): 135-41. DOI: 10.1016\/j.jaci.2018.05.029","DOI":"10.1016\/j.jaci.2018.05.029"},{"key":"57582","doi-asserted-by":"crossref","unstructured":"Newsom M, Bashyam AM, Balogh EA, Feldman SR, et al. New and Emerging Systemic Treatments for Atopic Dermatitis. Drugs. 2020; 80 (11): 1041-52. https:\/\/doi.org\/10.1007\/s40265-020-01335-7","DOI":"10.1007\/s40265-020-01335-7"},{"key":"57583","doi-asserted-by":"crossref","unstructured":"Singh R, Heron CE, Ghamrawi RI, Strowd LC, et al. Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis. ImmunoTargets Ther. 2020; 9: 255-72. DOI: 10.2147\/itt.s229667","DOI":"10.2147\/ITT.S229667"},{"key":"57584","doi-asserted-by":"crossref","unstructured":"LeBovidge JS, Elverson W, Timmons KG, Hawryluk EB, et al. Multidisciplinary interventions in the management of atopic dermatitis. J Allergy Clin Immunol. 2016; 138 (2): 325-34. http:\/\/dx.doi.org\/10.1016\/j.jaci.2016.04.003","DOI":"10.1016\/j.jaci.2016.04.003"},{"key":"57585","doi-asserted-by":"crossref","unstructured":"Borzutzky A, Larco JI, Luna PC, McElwee E, et al. Atopic Dermatitis in Latin America: A Roadmap to Address Data Collection, Knowledge Gaps, and Challenges. Dermatitis. 2022; 33 (6S): S83-S91. DOI: 10.1097\/DER.0000000000000904.","DOI":"10.1097\/DER.0000000000000904"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1228\/2062","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1228\/2706","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1228\/2062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:53:42Z","timestamp":1744214022000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":67,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9,11]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v70i3.1228","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"type":"electronic","value":"2448-9190"},{"type":"print","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2023,8,21]]}}}